Eszopiclone 3mg IS the US Equivalent
Eszopiclone 3mg is already the United States medication—there is no "equivalent" to find because eszopiclone itself is FDA-approved and marketed in the US under the brand name Lunesta. 1
Key Points About Eszopiclone in the US
FDA-Approved Formulations
Eszopiclone is available in the United States in three strengths 1:
- 1 mg tablets (blue, circular)
- 2 mg tablets (white, circular)
- 3 mg tablets (dark blue, circular)
Clinical Context
Eszopiclone is one of only three hypnotics with moderate-strength evidence for improving short-term sleep outcomes in adults with insomnia disorder (the others being zolpidem and suvorexant). 2 It was FDA-approved in December 2004 specifically for long-term treatment of insomnia, including both sleep onset and maintenance difficulties. 3
Dosing Recommendations
- Adults (18-64 years): 2-3 mg for sleep onset and/or maintenance 3
- Older adults (≥65 years): 2 mg for maintenance; 1 mg if primary complaint is difficulty falling asleep 3
Efficacy Evidence
Meta-analytic data demonstrates eszopiclone's effectiveness compared to placebo 4:
- Reduces sleep onset latency by 12 minutes
- Decreases wake time after sleep onset by 17 minutes
- Increases total sleep time by 28 minutes
These improvements are sustained from short-term (≤4 weeks) through long-term treatment (>6 months). 5, 4
Important Safety Considerations
Common Adverse Effects
The most frequent side effects include 4:
- Unpleasant taste (18% increased risk vs placebo)
- Dry mouth (4% increased risk)
- Somnolence (4% increased risk)
- Dizziness (3% increased risk)
Serious Warnings
FDA documents indicate risks for 2:
- Cognitive and behavioral changes
- Driving impairment
- Potential for tolerance and dependence (though less than benzodiazepines)
- Long-term observational data suggests associations with dementia, fractures, and major injury
Clinical Caveat
While eszopiclone shows moderate efficacy for short-term use, the absolute effect sizes are small, and long-term comparative effectiveness data remain limited. 2 The evidence quality is moderate for efficacy outcomes but based primarily on industry-sponsored trials with stringent enrollment criteria that may not reflect real-world patient populations.